MedTrace Logo

Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

NCT04812938 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2021-03-24

No results posted yet for this study

Summary

The aim of the project is to corroborate them on a large retrospective cohort of HGS-EOC and confirm the possibility of identify TP53 mutations in high grade endometrioid tumors.

This will consequently allow to confirm the previous results and define with a greater precision the temporal windows in which it will be possible to detect, through the TP53 analysis, tumor material by vaginal swab sampling. The results of the study will be the first step of a multiphase prospective validation program for the development of a novel approach for early diagnosis of EOC.

Conditions

Interventions

DIAGNOSTIC_TEST

Patients with Ovarian cancer and pap test available

Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.

Sponsors & Collaborators

  • Humanitas Hospital, Italy

    collaborator OTHER

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Paolo Zola, MD/PhD · Department of Surgical Science University of Turin

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2022-04-01
Completion
2022-10-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812938 on ClinicalTrials.gov